Ones To Watch News
Refine Search
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Biotechnology
ARYA Sciences Acquisition Corp IV , a publicly traded special purpose acquisition company (SPAC) sponsored by Perceptive Advisors, announced on Thursday that, due to existing market conditions, it has mutually agreed with Amicus Therapeutics terminate their previously announced business combination agreement, effective immediately. 25 February 2022
Biotechnology
London-listed Finnish biotech firm Faron Pharmaceuticals today announced updated survival data from Phase I/II MATINS (Macrophage Antibody To INhibit immune Suppression) study investigating the safety and efficacy of bexmarilimab, Faron’s wholly-owned, novel precision cancer immunotherapy candidate, which has the trade name Clevegen. 23 February 2022
Pharmaceutical
US cancer therapies specialist Karyopharm Therapeutics saw its shares drop as much as 31% Tuesday, on the news that its chief medical officer was stepping down, even though it also announced two prominent research appointments. 23 February 2022
Biotechnology
US biotech Adagio Therapeutics today outlined strategic initiatives for its ADG20 program, as well as research efforts to address SARS-CoV-2 and other coronaviruses. 22 February 2022
Biotechnology
US rare liver disease-focussed biotech Albireo Pharma said today that the UK’s National Institute for Health and Care Excellence (NICE) has issued guidance that recommends Bylvay (odevixibat) for the treatment of all types of progressive familial intrahepatic cholestasis (PFIC) in people aged six months and older. 22 February 2022
Biotechnology
Dutch thrombotic diseases specialist TargED Biopharmaceuticals has raised 39 million euros ($44 million) in a Series A financing to accelerate development of its lead compound, Microlyse. 22 February 2022
Biotechnology
German biotech BioNTech, which has earned billions of dollars through its COIVD-19 vaccine development with Pfizer (NYSE: PFE), is looking to expand its business into new areas. 22 February 2022
Biotechnology
Shares in US genetic medicines company Homology Medicines were set to open 37% lower on Monday following the release of bad news since Friday’s close. 21 February 2022
Biotechnology
Shares of UK respiratory disease focussed biotech Synairgen plunged more than 85% to 25.04 pence this morning, after it announced that the international Phase III SPRINTER trial of SNG001 in patients hospitalized with COVID-19 did not meet its primary or key secondary efficacy endpoints. 21 February 2022
Biotechnology
China-based biotech BeiGene today announced that BeiGene’s BTK inhibitor Brukinsa (zanubrutinib) has received approval from Swissmedic for the treatment of adult patients with Waldenström’s macroglobulinemia (WM). 17 February 2022
Biotechnology
US biotech Star Therapeutics has emerged from stealth mode with $100 million in financing and the ambition to be an innovation engine for rare disease therapies. 17 February 2022
Biotechnology
US clinical-stage biotech Legend Biotech Corporation managed to close up 2.2% yesterday, despite announcing that, on Friday, February 11, the company was informed by the US Food and Drug Administration (FDA) via email communication that its Phase I clinical trial for LB1901 has been placed on clinical hold. 16 February 2022
Pharmaceutical
French pharma ingredients company Novasep and USA-based Paratek Pharmaceuticals have signed an agreement to ramp up the commercial production of omadacycline, the active pharmaceutical ingredient (API) used for Paratek’s Nuzyra. 15 February 2022
Pharmaceutical
Switzerland-based Roivant Sciences has launched a new Vant subsidiary, Hemavant, which has entered into a licensing agreement with Japanese drugmaker Eisai for exclusive global rights to the investigational agent RVT-2001 (previously H3B-8800,) a potential first-in-class small molecule SF3B1 modulator. 15 February 2022
Pharmaceutical
Shares of specialty drugmaker BioDelivery Sciences International shot up 52% to $3.64 in pre-market trading today, after it agreed to be acquired by fellow USA-based Collegium Pharmaceuticals. 14 February 2022
Biotechnology
The US Food and Drug Administration (FDA) has blocked attempts to halt trials of Cassava Sciences’ experimental Alzheimer’s drug simufilam. 14 February 2022
Pharmaceutical
Shares of Bavarian Nordic were down 3.7% at 164.55 Danish kroner by late morning today, despite announcing that the US Food and Drug Administration has granted Breakthrough Therapy designation for the Danish company's vaccine candidate, MVA-BN RSV, for active immunization for prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults aged 60 years or older. 14 February 2022
Biotechnology
Dutch rare diseases biotech firm ProQR Therapeutics saw its shares plummet more than 74% to $1.45 today, as it announced that its pivotal Phase II/III Illuminate trial of sepofarsen for the treatment of CEP290-mediated Leber congenital amaurosis 10 (LCA10) did not meet its primary endpoint of best corrected visual acuity (BCVA) at Month 12. 11 February 2022
Biotechnology
A biotech company called Seismic Therapeutic has launched with the aim of advancing machine learning for immunology drug development. 10 February 2022
Biotechnology
US biotech firm Ventus Therapeutics, which is developing small molecule therapeutics across a broad range of disease indications, announced today the closing of a $140 million Series C financing. 9 February 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze